Prediction of new C-terminal Hsp90 inhibitors based on deguelin scaffold: homology modeling, virtual screening, QM/MM docking, MM/GBSA, and molecular dynamics simulations

Maryam Abbasi, Setareh Talaei, Gholamreza Farshidfar

Abstract


Background and purpose: The N-terminal Hsp90 inhibitors are promising targets for cancer treatment; however, inducing the heat shock response is one of the most significant limitations. A prominent way to overcome this limitation is by inhibiting the Hsp90 C-terminal domain.

Theoretical approach: In this study, a set of structure-based methods was engaged to predict the new C-terminal inhibitors. Since there was no human PDB structure of the Hsp90 C-terminal domain, homology modeling was done using the SWISS-MODEL server online. The 3D structure of the model was refined through energy minimization using molecular dynamics (MD) simulation for 10 ns. The active site of the created model was validated by novobiocin docking. Four steps of virtual screening, including HTVS, SP, XP, and QM/MM docking, were performed on the created library (151,332 compounds) based on 80% similarity to deguelin as the C-terminal inhibitor. The best-obtained compounds were introduced to MM-GBSA studies. Finally, the stability of the best compound was investigated using a 100 ns MD simulation.

Results/Findings: Four steps of virtual screening were performed on the created library. The extracted 46 compounds with the XP GlideScore of < -4.164 kcal/mol were introduced to MM-GBSA studies, and rescoring was done. The stability of compound CID_14018348, the best compound (∆Gbinding = -80.45 kcal/mol), was investigated using MD simulation.

Conclusion and implications: The compound CID_14018348 was identified as the most promising candidate through computational techniques; therefore, the computational methods outlined can be applied in the development of potent anticancer agents.

 

 


Keywords


C-terminal Hsp90 inhibitors; Deguelin; Homology modeling; MM/GBSA study; Molecular dynamic simulations; QM/MM docking; Virtual screening.

Full Text:

PDF

References


Liu J, Shu H, Xia Q, You Q, Wang L. Recent developments of HSP90 inhibitors: an updated patent review (2020-present). Expert Opin Ther Pat. 2024;34(1-2):1-15.DOI: 10.1080/13543776.2024.2327295.

Hoter A, El-Sabban ME, Naim HY. The HSP90 family: structure, regulation, function, and implications in health and disease. Int J Mol Sci. 2018;19(9):2560,1-33.DOI: 10.3390/ijms19092560.

Campanella C, Pace A, Caruso Bavisotto C, Marzullo P, Marino Gammazza A, Buscemi S, et al. Heat shock proteins in Alzheimer’s disease: role and targeting. Int J Mol Sci. 2018;19(9):2603,1-22.DOI: 10.3390/ijms19092603.

Shadrack DM, Swai HS, Hassanali A. A computational study on the role of water and conformational fluctuations in Hsp90 in response to inhibitors. J Mol Graph Model. 2020;96:107510.DOI: 10.1016/j.jmgm.2019.107510.

Mielczarek-Lewandowska A, Hartman ML, Czyz M. Inhibitors of HSP90 in melanoma. Apoptosis. 2020; 25(1-2):12-28.DOI: 10.1007/s10495-019-01577-1.

Toss A, Venturelli M, Peterle C, Piacentini F, Cascinu S, Cortesi L. Molecular biomarkers for prediction of targeted therapy response in metastatic breast cancer: trick or treat? Int J Mol Sci. 2017;18(1):85,1-24.DOI: 10.3390/ijms18010085.

Alimardan Z, Abbasi M, Khodarahmi G, Kashfi K, Hasanzadeh F, Aghaei M. Identification of new small molecules as dual FoxM1 and Hsp70 inhibitors using computational methods. Res Pharm Sci. 2022;17(6):635-656.DOI: 10.4103/1735-5362.359431.

Alosaimy AM, Abouzied AS, Alsaedi AMR, Alafnan A, Alamri A, Alamri MA, et al. Discovery of novel indene-based hybrids as breast cancer inhibitors targeting Hsp90: synthesis, bio-evaluation and molecular docking study. Arab J Chem. 2023;16(4):104569,1-13.DOI: 10.1016/j.arabjc.2023.104569.

Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature. 2003;425(6956):407-410.DOI: 10.1038/nature01913.

Miller DJ, Fort PE. Heat shock proteins regulatory role in neurodevelopment. Front Neurosci. 2018;12:821,1-15.DOI: 10.3389/fnins.2018.00821.

Sanchez J, Carter TR, Cohen MS, Blagg BSJ. Old and new approaches to target the Hsp90 chaperone. Curr Cancer Drug Targets. 2020;20(4):253-270.DOI: 10.2174/1568009619666191202101330.

Jaeger AM, Whitesell L. HSP90: enabler of cancer adaptation. Annu Rev Cancer Biol. 2019;3:275-297.DOI: 10.1146/annurev-cancerbio-030518-055533.

Tomašič T, Durcik M, Keegan BM, Skledar DG, Zajec Ž, Blagg BSJ, et al. Discovery of novel Hsp90 C-terminal inhibitors using 3D-pharmacophores derived from molecular dynamics simulations. Int J Mol Sci. 2020;21(18):6898,1-22.DOI: 10.3390/ijms21186898.

Bhatia S, Diedrich D, Frieg B, Ahlert H, Stein S, Bopp B, et al. Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response. Blood. 2018;132(3):307-320.DOI: 10.1182/blood-2017-10-810986.

Dernovšek J, Zajec Ž, Durcik M, Mašič LP, Gobec M, Zidar N, et al. Structure-activity relationships of benzothiazole-based Hsp90 C-terminal-domain inhibitors. Pharmaceutics. 2021;13(8):1283,1-30.DOI: 10.3390/pharmaceutics13081283.

Zajec Ž, Dernovšek J, Gobec M, Tomašič T. In silico discovery and optimisation of a novel structural class of Hsp90 C-terminal domain inhibitors. Biomolecules. 2022;12(7):884,1-23.DOI: 10.3390/biom12070884.

Donnelly A, Blagg BSJ. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. Curr Med Chem. 2008;15(26):2702-2717.DOI: 10.2174/092986708786242895.

Chang DJ, An H, Kim KS, Kim HH, Jung J, Lee JM, et al. Design, synthesis, and biological evaluation of novel deguelin-based heat shock protein 90 (HSP90) inhibitors targeting proliferation and angiogenesis. J Med Chem. 2012;55(24):10863-10884.DOI: 10.1021/jm301488q.

Lin ZY, Yun QZ, Wu L, Zhang TW, Yao TZ. Pharmacological basis and new insights of deguelin concerning its anticancer effects. Pharmacol Res. 2021;174:105935.DOI: 10.1016/j.phrs.2021.105935.

Lanka G, Bathula R, Bhargavi M, Potlapally SR. Homology modeling and molecular docking studies for the identification of novel potential therapeutics against human PHD3 as a drug target for type 2 diabetes mellitus. J Drug Delivery Ther. 2019;9(4):265-273.DOI: 10.22270/jddt.v9i4.3039.

Cuyàs E, Verdura S, Micol V, Joven J, Bosch-Barrera J, Encinar JA, et al. Revisiting silibinin as a novobiocin-like Hsp90 C-terminal inhibitor: computational modeling and experimental validation. Food Chem Toxicol. 2019;132:110645,1-12.DOI: 10.1016/j.fct.2019.110645.

Schrodinger L. Prime. Version 3.9. New York (NY); 2015.

Abraham MJ, Murtola T, Schulz R, Páll S, Smith JC, Hess B, et al. GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX. 2015;1-2:19-25.DOI: 10.1016/j.softx.2015.06.001.

Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML. Comparison of simple potential functions for simulating liquid water. J Chem Phys.1983;79(2):926-935.DOI: 10.1063/1.445869.

Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Cryst. 1993;26(2):283-291.DOI: 10.1107/S0021889892009944.

Wiederstein M, Sippl MJ. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res. 2007;35(suppl_2): W407-W410.DOI: 10.1093/nar/gkm290.

Schrödinger L. Schrödinger Release 2015-3: LigPrep. Schrödinger LLC, New York, NY; 2015.

Epik. Version 3.4. Schrödinger LLC. New York, NY; 2015.

Matts RL, Dixit A, Peterson LB, Sun L, Voruganti S, Kalyanaraman P, et al. Elucidation of the Hsp90 C-terminal inhibitor binding site. ACS Chem Biol. 2011;6(8):800-807.DOI: 10.1021/cb200052x.

Abbasi M, Mahboubi-Rabbani M, Kashfi K, Sadeghi-Aliabadi H. Prediction of dual NF-κB/IκB inhibitors using an integrative in-silico approaches. J Biomol Struct Dyn. 2023;41(23):14164-14178.DOI: 10.1080/07391102.2023.2178507.

Mobley DL, Dill KA. Binding of small-molecule ligands to proteins:“what you see” is not always “what you get”. Structure. 2009;17(4):489-498.DOI: 10.1016/j.str.2009.02.010.

Sousa da Silva AW, Vranken WF. ACPYPE-AnteChamber PYthon Parser interface. BMC Res Notes. 2012;5:367,1-8.DOI: 10.1186/1756-0500-5-367.

Makarewicz T, Kaźmierkiewicz R. Molecular dynamics simulation by GROMACS using GUI plugin for PyMOL. J Chem Inf Model. 2013;53(5):1229-1234.DOI: 10.1021/ci400071x


Refbacks

  • There are currently no refbacks.


Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.